Accès ouvert

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission

Article scientifique 2020 Anglais

Résumé

Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6-18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).

Citer ce document

Nyakato, P., Davies, M., Technau, K., Fatti, G., Rabie, H., Tanser, F., Boulle, A., Wood, R., Eley, B., Sawry, S., Giddy, J., Sipambo, N., Kuhn, L., Fairlie, L. (2020). Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. https://doi.org/10.1371/journal.pone.0233693

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Patience Nyakato Mary‐Ann Davies Karl‐Günter Technau Geoffrey Fatti Helena Rabie Frank Tanser Andrew Boulle Robin Wood Brian Eley Shobna Sawry Janet Giddy Nosisa Sipambo Louise Kuhn Lee Fairlie

Statistiques

Consultations : 1

Téléchargements : 0